Shenzhen Chipscreen Biosciences (SHA:688321) obtained the marketing approval of Macau's drug regulator for its chiglitazar sodium tablets.
The drug, sold under the trade names Shuangluoping and Bilessglu, is indicated for type two diabetes as both monotherapy and in combination with metformin, according to a Friday filing with the Shanghai bourse.
Shares of the drug developer closed 2% lower Friday.
Indian benchmark indices closed lower on Friday, ending a two-day winning streak, as profit booking intensified amid weak global cues, higher crude oil prices, and continued pressure on the rupee.The BSE Sensex fell 160.73 points, or 0.2%, to close at 75,237.99, while the NSE Nifty 50 declined 46.10 points, or 0.2%, to settle at 23,643.50.Market sentiment stayed subdued as investors tracked a sharp rise in crude oil prices and the rupee's slide to a fresh record low of over 96 rupees against the U.S. dollar. Persistent foreign outflows added to pressure on the domestic currency.In corporate developments, Indobell Insulations (BOM:544334) secured a 13.9 million rupee domestic contract from Bharat Heavy Electricals (NSE:BHEL, BOM:500103) for thermal insulation work, scheduled for completion by July 2027.Lupin (NSE:LUPIN, BOM:500257) announced the launch of Atharv Ability in New Delhi, a neuro-rehabilitation center focused on multidisciplinary treatment for neurological disorders, as per a stock exchange filing.Separately, Indian billionaire Gautam Adani and Sagar Adani reached a settlement with the U.S. Securities and Exchange Commission in a civil case, agreeing to pay civil penalties of $6 million and $12 million, respectively, without admitting or denying the allegations.
Recruit's (TYO:6098) profit attributable to owners of the parent rose 22% to 496.9 billion yen for the fiscal year 2025 from 408.5 billion yen a year earlier.The employment agency company's earnings per share increased to 347.59 yen from 268.32 yen a year ago, according to a Tokyo bourse filing on Friday.Revenue jumped 3.9% to 3.697 trillion yen for the period ended March 31 from 3.557 trillion yen in the prior year.It declared a final dividend of 12.50 yen per share.For the fiscal year 2026, the company expects attributable profit of 623 billion yen, basic EPS of 447.00 yen, and revenue of 4.030 trillion yen.Recruit plans to pay interim and year-end dividends of 13 yen per share each, which is higher than the amount paid the prior year.
Mizuho Financial Group's (TYO:8411) profit attributable to owners of the parent jumped 41% to 1.249 trillion yen in the fiscal year 2025 from 885.4 billion yen a year earlier.The bank's earnings per share increased to 502.92 yen from 350.20 yen a year ago, according to a Tokyo bourse filing on Friday.Ordinary income inched up 0.6% to 9.085 trillion yen in the year ended March 31 from 9.030 trillion yen in the prior year.Mizuho Financial declared a final dividend of 72.50 yen per share, payable from June 8.For fiscal year 2026, the bank expects attributable profit of 1.3 trillion yen and EPS of 533.10 yen.Mizuho Financial plans to pay interim and year-end dividends of 75 yen per share each for the year.